The AngioSculpt scoring balloon catheter multi-center coronary bifurcation study is a prospective, multi-center, single arm study evaluating the AngioSculpt as the primary treatment of the side-branch vessel along with an approved drug-eluting stent for the main branch vessel. Patients will be followed at one month for safety outcomes and at nine months for clinical evidence of restenosis.
The Agility trial will enroll 100 patients with coronary bifurcation lesions at eight premier interventional cardiology programs in the US and follow these patients for nine months.
Gary Gershony, co-founder and chief medical officer of AngioScore, said: “The AngioSculpt represents a significant improvement over conventional angioplasty balloon catheters for the treatment of challenging lesions because of its ability to achieve more predictable luminal expansion and a lower rate of dissection.”